Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
NCT03297775
Summary
The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA). The investigators hypothesize that there are common core elements (e.g. clinical features, genetic variants, and/or biologic markers) between other forms of ILD (e.g. idiopathic pulmonary fibrosis, IPF) and subclinical RA-ILD that places individuals at risk for the development of lung disease.
Eligibility
Inclusion Criteria: 1. ≥ 45years old 2. Diagnosis of RA using the 2010 American College of Rheumatology (ACR) criteria Exclusion Criteria: 1. Inability to give informed consent 2. Pregnant women 3. History of interstitial lung disease 4. Evidence of other causes of diffuse parenchymal lung disease such as infection, drug toxicity, other autoimmune processes, etc. 5. Subjects over the age of 90 years old or less than 45 years old
Conditions3
Locations1 site
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT03297775